<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043847</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0201</org_study_id>
    <secondary_id>2013-0201</secondary_id>
    <nct_id>NCT02043847</nct_id>
  </id_info>
  <brief_title>Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03)</brief_title>
  <acronym>BMT-03</acronym>
  <official_title>BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase I trial, patients with relapsed or refractory multiple myeloma will receive&#xD;
      standard high dose melphalan with autologous stem cell rescue. In addition the pre-transplant&#xD;
      conditioning will include targeted total marrow irradiation (TMI). This conventional 3+3&#xD;
      phase I trial will increase the dose of TMI until the maximum tolerated dose (MTD) is&#xD;
      reached. Initial patients enrolled will receive the lowest possible dose of 3Gy. Maximum dose&#xD;
      will be 9Gy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2014</start_date>
  <completion_date type="Actual">September 14, 2016</completion_date>
  <primary_completion_date type="Actual">September 14, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of TMI</measure>
    <time_frame>Up to 60 days post-transplant.</time_frame>
    <description>To establish the maximal tolerated dose of total marrow irradiation which can be added to high dose melphalan conditioning in patients with multiple myeloma undergoing autologous stem cell transplant for relapsed/ refractory myeloma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 1 year post-transplant.</time_frame>
    <description>To evaluate progression free survival (PFS) and in patients with multiple myeloma (relapsed or refractory) undergoing autologous stem cell transplant using the combination of high dose melphalan and total marrow irradiation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Multiple Myeloma, Relapsed</condition>
  <condition>Multiple Myeloma, Refractory to Standard Treatment</condition>
  <arm_group>
    <arm_group_label>Total Marrow Irradiation (TMI) 3Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3Gy with standard high dose melphalan prior to autologous stem cell rescue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Marrow Irradiation (TMI) 6Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6Gy with standard high dose melphalan prior to autologous stem cell rescue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Marrow Irradiation (TMI) 9Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9Gy with standard high dose melphalan prior to autologous stem cell rescue</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Marrow Irradiation</intervention_name>
    <description>Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 3Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 3Gy</arm_group_label>
    <other_name>Alkeran ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim (G-CSF)</intervention_name>
    <description>Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC &gt; 1000/mm^3 over period of 3 days.</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 3Gy</arm_group_label>
    <other_name>Neupogen®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous transplant</intervention_name>
    <description>Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with autologous stem cell rescue</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 3Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Marrow Irradiation</intervention_name>
    <description>Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 6Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 6Gy</arm_group_label>
    <other_name>Alkeran ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim (G-CSF)</intervention_name>
    <description>Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC &gt; 1000/mm^3 over period of 3 days</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 6Gy</arm_group_label>
    <other_name>Neupogen®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous transplant</intervention_name>
    <description>Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with autologous stem cell rescue</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 6Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Marrow Irradiation</intervention_name>
    <description>Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 9Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 9Gy</arm_group_label>
    <other_name>Alkeran ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim (G-CSF)</intervention_name>
    <description>Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC &gt; 1000/mm^3 over period of 3 days</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 9Gy</arm_group_label>
    <other_name>Neupogen®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous transplant</intervention_name>
    <description>Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with autologous stem cell rescue</description>
    <arm_group_label>Total Marrow Irradiation (TMI) 9Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients meeting criteria for symptomatic myeloma&#xD;
&#xD;
          2. Patients who have progressive myeloma following initial induction (patients may have&#xD;
             received any number of treatment regimens including prior autologous transplant)&#xD;
&#xD;
          3. Patient age 18-75 years at time of enrollment&#xD;
&#xD;
          4. Karnofsky performance status of ≥70&#xD;
&#xD;
          5. Cardiac function: LVEF &gt;40%&#xD;
&#xD;
          6. Hepatic: Bilirubin &lt;2x upper limit of normal and ALT and AST &lt; 2.5x the upper limit of&#xD;
             normal&#xD;
&#xD;
          7. Renal: Creatinine clearance of &gt;30mL/min, estimated or calculated&#xD;
&#xD;
          8. Pulmonary: DLCO, FEV1, FVC &gt;50% of predicted (after correction for hemoglobin)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with diagnosis of plasma cell leukemia&#xD;
&#xD;
          2. Patients with truly non secretory myeloma (patients with light chain disease are&#xD;
             eligible)&#xD;
&#xD;
          3. Pregnant or breast-feeding&#xD;
&#xD;
          4. Uncontrolled viral, fungal or bacterial infection Note: Infection is permitted if&#xD;
             there is evidence of response to medication. Eligibility of HIV infected patients will&#xD;
             be determined on a case-by-case basis.&#xD;
&#xD;
          5. Patients who have undergone prior allogeneic stem cell transplant&#xD;
&#xD;
          6. Prior solid organ transplant&#xD;
&#xD;
          7. Patients receiving prior radiation to more than 20% of bone marrow containing areas&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pritesh Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Pritesh Patel, MD</investigator_full_name>
    <investigator_title>Faculty, Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Progressive Disease</keyword>
  <keyword>Symptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

